Introduction: The differentiation of digestive tumors very often requires the use of techniques currently not widely in use in the Democratic Republic of Congo (DRC), such as immunohistochemistry. This is perfectly verified for GISTs whose precise, or at least highly certain, diagnosis can only be made using immunohistochemical markers. This underuse of these techniques due to lack of equipment and human skills explains the limited epidemiological data available to date, thus leading to untargeted and too often late treatment of patients. Research question: What contribution can immunohistochemical markers make to the diagnosis of digestive tract tumours? Objective: Discuss the contribution of immunohistochemical markers in the diagnosis of GIST and provide basic data on the epidemiology of these nosological entities in Kinshasa. Methodology: This was a retrospective study carried out at the LEBOMA private anatomy and pathological cytology centre. The main inclusion criterion was any digestive tract block or slide whose diagnosis of GIST had been requalified after review by at least 2 pathologists. An immuhistochemical study was performed using an automated technique (with a Ventana XT machine) using a panel of antibodies: CD-117 and DOG-1 which are listed in the literature as strongly correlated with the occurrence of GIST, all slides were made at Hj Hospital using an OLYMPUS BX41 co-observation microscope.Results: Of 601 cases of digestive tumors recorded during the concerned period, 32 (5.32%) concerned GIST. This prevalence was confirmed by our immunohistochemical results where the expression of CD117 and that of DOG-1 were positive in 90.6% and 100% of cases which prevalence is high compared with the worldwide prevalence according to the literature, respectively. The distribution of the patients concerned was made with a sex ratio of 1.6 women/men with a median age of 53 years. Most cases (81%) had a gastric location and were fusiform GISTs. Conclusion: Gastrointestinal stromal tumours, although rare and underestimated, account for 5.32% of cases in the DRC. This is a considerable and high prevalence compared with the world average. To the best of our knowledge, no studies have been carried out on these aspects in the DRC, which explains the importance of this study. The results of this research demonstrated the contribution of these 2 markers as specific and effective biomarkers for optimal and differential diagnosis in GIST. In view of the above, it is therefore more than necessary to popularise
References
[1]
Katz, S.C. and DeMatteo, R.P. (2008) Gastrointestinal Stromal Tumors 202 Zhao and Yue. Gastrointestinal Stromal Tumor and Leiomyosarcomas. Journal of Surgical Oncology, 97, 350-359. https://doi.org/10.1002/jso.20970
[2]
Miettinen, M. and Lasota, J. (2006) Gastrointestinal Stromal Tumors: Pathology and Prognosis at Different Sites. Seminars in Diagnostic Pathology, 23, 70-83. https://doi.org/10.1053/j.semdp.2006.09.001
[3]
Joensuu, H., Fletcher, C., Dimitrijevic, S., et al. (2002) Management of Malignant Gastrointestinal Stromal Tumours. The Lancet Oncology, 3, 655-664. https://doi.org/10.1016/S1470-2045(02)00899-9
[4]
Agaimy, A., Dirnhofer, S., Wunsch, P.H., Terracciano, L.M., Tornillo, L. and Bihl, M.P. (2008) Multiple Sporadic Gastrointestinal Stromal Tumors (GISTs) of the Proximal Stomach Are Caused by Different Somatic KIT Mutations Suggesting a Field Effect. The American Journal of Surgical Pathology, 32, 1553-1559. https://doi.org/10.1097/PAS.0b013e31817587ea
[5]
Kindblom, L.G., Remotti, H.E., Aldenborg, F., et al. (1998) Gastrointestinal Pacemaker Cell Tumor (GIPACT): Gastrointestinal Stromal Tumors Show Phenotypic Characteristics of the Interstitial Cells of 144 Cajal. The American Journal of Pathology, 152, 1259-1269.
[6]
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., et al. (1998) Gain-of-Function Mutations of c-kit in Human Gastrointestinal Stromal Tumors. Science, 279, 577-580. https://doi.org/10.1126/science.279.5350.577
[7]
Hornick, J.L. and Fletcher, C.D.M. (2004) The Significance of KIT (CD117) in Gastrointestinal Stromal Tumors. International Journal of Surgical Pathology, 12, 93-97. https://doi.org/10.1177/106689690401200201
[8]
Sarlomo-Rikala, M., Kovatich, A.J., Barusevicius, A. and Miettinen, M. (1998) CD117, a Sensitive Marker for Gastrointestinal Stromal Tumors That Is More Specific than CD34. Modern Pathology, 11, 728-734.
[9]
Liegl, B., Hornick, J.L., Corless, C.L. and Fletcher, C.D. (2009) Monoclonal Antibody DOG1.1 Shows Higher Sensitivity than KIT in the Diagnosis of Gastrointestinal Stromal Tumors, Including Unusual Subtypes. The American Journal of Surgical Pathology, 33, 437-446. https://doi.org/10.1097/PAS.0b013e318186b158
[10]
Liu, X., Qiu, H., Zhang, P., et al. (2018) Prognostic Factors of Primary Gastrointestinal Stromal Tumors: A Cohort Study Based on High-Volume Centers. Chinese Journal of Cancer Research, 30, 61-71. https://doi.org/10.21147/j.issn.1000-9604.2018.01.07
[11]
Fletcher, C.D., Berman, J.J., Corless, C., et al. (2002) Diagnosis of Gastrointestinal Stromal Tumors: A Consensus Approach. Human Pathology, 33, 459-465. https://doi.org/10.1053/hupa.2002.123545
[12]
Shen, Y.Y., Li, X.Q., Yang, L.X., Fang, Y., Nie, M.M., He, Z.R., Hou, Y.Y., Cao, H., Wang, M. and Shen, K.T. (2021) Clinicopathological Features and Prognosis of Gastrointestinal Stromal Tumors with KIT/PDGFRA Gene “Homozygous Mutation”: A Multicenter Retrospective Cohort Study. Chinese Journal of Gastrointestinal Surgery, 24, 804-813.
[13]
Corless, C.L., Schroeder, A., Griffith, D., Town, A., McGreevey, L., Harrell, P., et al. (2005) PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and in Vitro Sensitivity to Imatinib. Journal of Clinical Oncology, 23, 5357-5364. https://doi.org/10.1200/JCO.2005.14.068
[14]
Gheorghe, M., Predescu, D., Iosif, C., Ardeleanu, C., Băcanu, F. and Constantinoiu, S. (2014) Clinical and Therapeutic Considerations of GIST. Journal of Medicine and Life, 7, 139-149.
[15]
DeMatteo, R.P., Lewis, J.J., Leung, D., et al. (2000) Two Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival. Annals of Surgery, 231, 51-58. https://doi.org/10.1097/00000658-200001000-00008
[16]
Nilsson, B., Bumming, P., Meis-Kindblom, J.M., et al. (2005) Gastrointestinal Stromal Tumors: The Incidence, Prevalence, Clinical Course, and Prognostication in the Preimatinib Mesylate Era—A Population-Based Study in Western Sweden. Cancer, 103, 821-829. https://doi.org/10.1002/cncr.20862
[17]
Martin-Broto, J., Martinez-Marín, V., Serrano, C., Hindi, N., López-Guerrero, J.A., Bisculoa, M., Ramos-Asensio, R., et al. (2017) Gastrointestinal Stromal Tumors (GISTs): SEAP-SEOM Consensus on Pathologic and Molecular Diagnosis. Clinical and Translational Oncology, 19, 536-545. https://doi.org/10.1007/s12094-016-1581-2
[18]
Miettinen, M., Killian, J.K., Wang, Z.F., Lasota, J., Lau, C., Jones, L., et al. (2013) Immunohistochemical Loss of Succinate Dehydrogenase Subunit A (SDHA) in Gastrointestinal Stromal Tumors (GISTs) Signals SDHA Germline Mutation. The American Journal of Surgical Pathology, 37, 234-240. https://doi.org/10.1097/PAS.0b013e3182671178
[19]
Tryggvason, G., Gislason, H.G., Magnusson, M.K., et al. (2005) Gastrointestinal Stromal Tumors in Iceland, 1990-2003, the Icelandic GIST Study, a Population-Based Incidence and Pathologic Risk Stratification Study. International Journal of Cancer, 117, 289-293. https://doi.org/10.1002/ijc.21167
[20]
Miettinen, M. and Lasota, J. (2011) Histopathology of Gastrointestinal Stromal Tumor. Journal of Surgical Oncology, 104, 865-873. https://doi.org/10.1002/jso.21945
[21]
Appelman, H.D. (1990) Mesenchymal Tumors of the Gut: Histological Perspectives, New Approaches, New Results, and Does It Make Any Difference. Monographs in Pathology, 31, 220-246.
[22]
Guler, B., Ozyılmaz, F., Tokuc, B., Can, N. and Taştekin, E. (2015) Histopathological Features of Gastrointestinal Stromal Tumors and the Contribution of DOG1 Expression to the Diagnosis. Balkan Medical Journal, 32, 388-396. https://doi.org/10.5152/balkanmedj.2015.15912
[23]
Şahin, S., Ekinci, Ö., Seçkin, S. and Dursun, A. (2017) The Diagnostic and Prognostic Utility of DOG1 Expression on Gastrointestinal Stromal Tumors. Turk Patoloji Dergisi, 33, 1-8. https://doi.org/10.5146/tjpath.2016.01376
[24]
Kiśluk, J., Zińczuk, J., Kemona, A., Guzińska-Ustymowicz, K., Żurawska, J. and Kędra, B. (2016) Expression of CD117, DOG-1, and IGF-1R in Gastrointestinal Stromal Tumours—An Analysis of 70 Cases from 2004 to 2010. Przegla̜d Gastroenterologiczny, 11, 115-122. https://doi.org/10.5114/pg.2015.52587
[25]
Wang, C., Jin, M.S., Zou, Y.B., Gao, J.N., Li, X.B., Peng, F., Wang, H.Y., Wu, Z.D., Wang, Y.P. and Duan, X.M. (2013) Diagnostic Significance of DOG-1 and PKC-θ Expression and C-Kit/PDGFRA Mutations in Gastrointestinal Stromal Tumours. Scandinavian Journal of Gastroenterology, 48, 1055-1065. https://doi.org/10.3109/00365521.2013.816770